Cargando…

Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes

The rapid emergence of SARS-CoV-2 variants is fueling the recent waves of the COVID-19 pandemic. Here, we assessed ACE2 binding and antigenicity of Mu (B.1.621) and A.2.5 Spikes. Both these variants carry some mutations shared by other emerging variants. Some of the pivotal mutations such as N501Y a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Debashree, Tauzin, Alexandra, Laumaea, Annemarie, Gong, Shang Yu, Bo, Yuxia, Guilbault, Aurélie, Goyette, Guillaume, Bourassa, Catherine, Gendron-Lepage, Gabrielle, Medjahed, Halima, Richard, Jonathan, Moreira, Sandrine, Côté, Marceline, Finzi, Andrés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780535/
https://www.ncbi.nlm.nih.gov/pubmed/35062348
http://dx.doi.org/10.3390/v14010144
_version_ 1784637862220660736
author Chatterjee, Debashree
Tauzin, Alexandra
Laumaea, Annemarie
Gong, Shang Yu
Bo, Yuxia
Guilbault, Aurélie
Goyette, Guillaume
Bourassa, Catherine
Gendron-Lepage, Gabrielle
Medjahed, Halima
Richard, Jonathan
Moreira, Sandrine
Côté, Marceline
Finzi, Andrés
author_facet Chatterjee, Debashree
Tauzin, Alexandra
Laumaea, Annemarie
Gong, Shang Yu
Bo, Yuxia
Guilbault, Aurélie
Goyette, Guillaume
Bourassa, Catherine
Gendron-Lepage, Gabrielle
Medjahed, Halima
Richard, Jonathan
Moreira, Sandrine
Côté, Marceline
Finzi, Andrés
author_sort Chatterjee, Debashree
collection PubMed
description The rapid emergence of SARS-CoV-2 variants is fueling the recent waves of the COVID-19 pandemic. Here, we assessed ACE2 binding and antigenicity of Mu (B.1.621) and A.2.5 Spikes. Both these variants carry some mutations shared by other emerging variants. Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant. Similarly, the L452R mutation of B.1.617.2 (Delta) variant is present in A.2.5. In this study, we observed that these Spike variants bound better to the ACE2 receptor in a temperature-dependent manner. Pseudoviral particles bearing the Spike of Mu were similarly neutralized by plasma from vaccinated individuals than those carrying the Beta (B.1.351) and Delta (B.1.617.2) Spikes. Altogether, our results indicate the importance of measuring critical parameters such as ACE2 interaction, plasma recognition and neutralization ability of each emerging variant.
format Online
Article
Text
id pubmed-8780535
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87805352022-01-22 Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes Chatterjee, Debashree Tauzin, Alexandra Laumaea, Annemarie Gong, Shang Yu Bo, Yuxia Guilbault, Aurélie Goyette, Guillaume Bourassa, Catherine Gendron-Lepage, Gabrielle Medjahed, Halima Richard, Jonathan Moreira, Sandrine Côté, Marceline Finzi, Andrés Viruses Communication The rapid emergence of SARS-CoV-2 variants is fueling the recent waves of the COVID-19 pandemic. Here, we assessed ACE2 binding and antigenicity of Mu (B.1.621) and A.2.5 Spikes. Both these variants carry some mutations shared by other emerging variants. Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant. Similarly, the L452R mutation of B.1.617.2 (Delta) variant is present in A.2.5. In this study, we observed that these Spike variants bound better to the ACE2 receptor in a temperature-dependent manner. Pseudoviral particles bearing the Spike of Mu were similarly neutralized by plasma from vaccinated individuals than those carrying the Beta (B.1.351) and Delta (B.1.617.2) Spikes. Altogether, our results indicate the importance of measuring critical parameters such as ACE2 interaction, plasma recognition and neutralization ability of each emerging variant. MDPI 2022-01-14 /pmc/articles/PMC8780535/ /pubmed/35062348 http://dx.doi.org/10.3390/v14010144 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Chatterjee, Debashree
Tauzin, Alexandra
Laumaea, Annemarie
Gong, Shang Yu
Bo, Yuxia
Guilbault, Aurélie
Goyette, Guillaume
Bourassa, Catherine
Gendron-Lepage, Gabrielle
Medjahed, Halima
Richard, Jonathan
Moreira, Sandrine
Côté, Marceline
Finzi, Andrés
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
title Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
title_full Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
title_fullStr Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
title_full_unstemmed Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
title_short Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
title_sort antigenicity of the mu (b.1.621) and a.2.5 sars-cov-2 spikes
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780535/
https://www.ncbi.nlm.nih.gov/pubmed/35062348
http://dx.doi.org/10.3390/v14010144
work_keys_str_mv AT chatterjeedebashree antigenicityofthemub1621anda25sarscov2spikes
AT tauzinalexandra antigenicityofthemub1621anda25sarscov2spikes
AT laumaeaannemarie antigenicityofthemub1621anda25sarscov2spikes
AT gongshangyu antigenicityofthemub1621anda25sarscov2spikes
AT boyuxia antigenicityofthemub1621anda25sarscov2spikes
AT guilbaultaurelie antigenicityofthemub1621anda25sarscov2spikes
AT goyetteguillaume antigenicityofthemub1621anda25sarscov2spikes
AT bourassacatherine antigenicityofthemub1621anda25sarscov2spikes
AT gendronlepagegabrielle antigenicityofthemub1621anda25sarscov2spikes
AT medjahedhalima antigenicityofthemub1621anda25sarscov2spikes
AT richardjonathan antigenicityofthemub1621anda25sarscov2spikes
AT moreirasandrine antigenicityofthemub1621anda25sarscov2spikes
AT cotemarceline antigenicityofthemub1621anda25sarscov2spikes
AT finziandres antigenicityofthemub1621anda25sarscov2spikes